LogicBio Therapeutics (NASDAQ:LOGC) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.
Volatility & Risk
LogicBio Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for LogicBio Therapeutics and Aptose Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LogicBio Therapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 191.97%. Aptose Biosciences has a consensus target price of $12.00, suggesting a potential upside of 57.48%. Given LogicBio Therapeutics’ higher possible upside, equities research analysts plainly believe LogicBio Therapeutics is more favorable than Aptose Biosciences.
Earnings and Valuation
This table compares LogicBio Therapeutics and Aptose Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LogicBio Therapeutics||N/A||N/A||-$40.13 million||($1.78)||-3.85|
|Aptose Biosciences||N/A||N/A||-$26.28 million||($0.52)||-14.65|
Aptose Biosciences is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
52.8% of LogicBio Therapeutics shares are held by institutional investors. Comparatively, 39.9% of Aptose Biosciences shares are held by institutional investors. 49.9% of LogicBio Therapeutics shares are held by company insiders. Comparatively, 7.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares LogicBio Therapeutics and Aptose Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aptose Biosciences beats LogicBio Therapeutics on 6 of the 9 factors compared between the two stocks.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.